[go: up one dir, main page]

CY1113348T1 - Χρησιμοποιηση ενωσεων c-(2-φαινυλο-κυκλοεξυλο)-μεθυλαμινης για τη θεραπεια φοβικων διαταραχων - Google Patents

Χρησιμοποιηση ενωσεων c-(2-φαινυλο-κυκλοεξυλο)-μεθυλαμινης για τη θεραπεια φοβικων διαταραχων

Info

Publication number
CY1113348T1
CY1113348T1 CY20111100588T CY111100588T CY1113348T1 CY 1113348 T1 CY1113348 T1 CY 1113348T1 CY 20111100588 T CY20111100588 T CY 20111100588T CY 111100588 T CY111100588 T CY 111100588T CY 1113348 T1 CY1113348 T1 CY 1113348T1
Authority
CY
Cyprus
Prior art keywords
cyclohexyl
dimethylaminomethyl
phenol
methoxyphenyl
methylamine
Prior art date
Application number
CY20111100588T
Other languages
English (en)
Inventor
Petra Bloms-Funke
Werner Englberger
Hagen-Heinrich Hennies
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1113348T1 publication Critical patent/CY1113348T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά τη χρησιμοποίηση [2-(3-μεθοξυφαινυλο)-κυκλοεξυλομεθυλο]-διμεθυλαμίνης και των μεταβολιτών της για την παρασκευή ενός φαρμάκου για τη θεραπεία καταστάσεων φόβου ή για την παρασκευή ενός ενισχυτικού μέσου για τυποποιημένα αντικαταθλιπτικά και μεθόδους για τη θεραπεία καταστάσεων φόβου ή καταθλίψεων.
CY20111100588T 2003-11-28 2011-06-21 Χρησιμοποιηση ενωσεων c-(2-φαινυλο-κυκλοεξυλο)-μεθυλαμινης για τη θεραπεια φοβικων διαταραχων CY1113348T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10356362A DE10356362A1 (de) 2003-11-28 2003-11-28 Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie von Angststörungen
EP04819227A EP1686984B1 (de) 2003-11-28 2004-11-26 Verwendung von c-(2-phenyl-cyclohexyl)-methylaminverbindungen zur therapie von angststörungen

Publications (1)

Publication Number Publication Date
CY1113348T1 true CY1113348T1 (el) 2016-06-22

Family

ID=34609453

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100588T CY1113348T1 (el) 2003-11-28 2011-06-21 Χρησιμοποιηση ενωσεων c-(2-φαινυλο-κυκλοεξυλο)-μεθυλαμινης για τη θεραπεια φοβικων διαταραχων
CY20121100904T CY1113162T1 (el) 2003-11-28 2012-09-28 Χρησιμοποιηση ενωσεων c-(2-φαινυλο-κυκλοεξυλο)-μεθυλαμινης για τη θεραπεια φοβικων διαταραχων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100904T CY1113162T1 (el) 2003-11-28 2012-09-28 Χρησιμοποιηση ενωσεων c-(2-φαινυλο-κυκλοεξυλο)-μεθυλαμινης για τη θεραπεια φοβικων διαταραχων

Country Status (14)

Country Link
US (3) US20060258741A1 (el)
EP (2) EP1686984B1 (el)
JP (1) JP5013875B2 (el)
AT (1) ATE509626T1 (el)
CA (1) CA2546672C (el)
CY (2) CY1113348T1 (el)
DE (1) DE10356362A1 (el)
DK (2) DK1686984T3 (el)
ES (2) ES2362752T3 (el)
HR (1) HRP20110608T1 (el)
PL (2) PL1970060T3 (el)
PT (2) PT1686984E (el)
SI (2) SI1970060T1 (el)
WO (1) WO2005051375A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050182131A1 (en) * 2002-07-19 2005-08-18 Gruenenthal Gmbh 1-Phenyl-2-dimethylaminomethyl cyclohexane compounds and therapies for depressive symptoms, pain and incontinence
DE102005034974A1 (de) * 2005-07-22 2007-04-19 Grünenthal GmbH Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen
DE102005034973A1 (de) * 2005-07-22 2007-02-15 Grünenthal GmbH Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen
DE102005061428A1 (de) * 2005-12-22 2007-08-16 Grünenthal GmbH Substituierte Cyclohexylmethyl-Derivate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
US6387956B1 (en) * 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
DE10059411A1 (de) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Verwendung von 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10146275A1 (de) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
AU2002364517A1 (en) * 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
DE10233048A1 (de) * 2002-07-19 2004-01-29 Grünenthal GmbH Verwendung von 1-Phenyl-3dimethylamino-propanverbindungen zur Therapie von depressiven Symptomatiken
PT1562567T (pt) * 2002-11-22 2017-08-24 Gruenenthal Gmbh Combinação de analgésicos selecionados e inibidores da cox-ii
DE10254785A1 (de) * 2002-11-22 2004-06-03 Grünenthal GmbH Kombination ausgewählter Analgetika mit COX II-Inhibitoren
DE102005011517A1 (de) * 2005-03-10 2006-09-21 Grünenthal GmbH Transdermales therapeutisches System zur Verabreichung von Analgetika
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation

Also Published As

Publication number Publication date
DK1970060T3 (da) 2012-10-01
PL1686984T3 (pl) 2011-10-31
EP1970060B9 (de) 2013-01-09
CA2546672C (en) 2013-01-22
ES2362752T3 (es) 2011-07-12
WO2005051375A1 (de) 2005-06-09
EP1970060A2 (de) 2008-09-17
US20060258741A1 (en) 2006-11-16
JP2007512288A (ja) 2007-05-17
EP1686984A1 (de) 2006-08-09
EP1686984B1 (de) 2011-05-18
PL1970060T3 (pl) 2012-11-30
ES2390931T3 (es) 2012-11-19
DK1686984T3 (da) 2011-06-20
US8084497B2 (en) 2011-12-27
DE10356362A1 (de) 2005-06-23
CY1113162T1 (el) 2016-04-13
EP1970060B1 (de) 2012-08-29
PT1686984E (pt) 2011-05-30
US20100249225A1 (en) 2010-09-30
ATE509626T1 (de) 2011-06-15
HRP20110608T1 (hr) 2011-10-31
JP5013875B2 (ja) 2012-08-29
EP1970060A3 (de) 2009-04-15
SI1686984T1 (sl) 2011-07-29
US20100004341A1 (en) 2010-01-07
CA2546672A1 (en) 2005-06-09
PT1970060E (pt) 2012-10-02
SI1970060T1 (sl) 2012-10-30

Similar Documents

Publication Publication Date Title
US6001884A (en) Calcium receptor-active molecules
SI2010531T1 (sl) Spirociklični cikloheksanski derivati z analgetskim učinkom
CY1113162T1 (el) Χρησιμοποιηση ενωσεων c-(2-φαινυλο-κυκλοεξυλο)-μεθυλαμινης για τη θεραπεια φοβικων διαταραχων
AU2009244082A1 (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
RU2012152639A (ru) Пиколинамидные и пиримидин-4-карбоксамидные соединения, способ их получения и фармацевтическая композиция, включающая их
EP0787122A2 (en) Calcium receptor-active compounds
JP2017527604A5 (el)
MXPA06012505A (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central.
EA200800430A1 (ru) Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов
RU2007139543A (ru) Производные бензодиоксана и бензодиоксолана и их применение
US20090318451A1 (en) Morpholine dopamine agonists for the treatment of pain
JP2012144545A (ja) アルファ−２−デルタリガンドとセロトニン／ノルアドレナリン再取込み阻害薬を含む組合せ
NZ585085A (en) Method of treating arthritis using arylsulfonamide compounds
US20230192588A1 (en) Cannabidiolic acid (cbda) derivatives and uses thereof
JP2006522030A5 (el)
JP2012036212A (ja) ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置
JP6605447B2 (ja) ジスキネジアおよび関連障害を治療する方法
TWI441631B (zh) 有效於治療精神障礙之α－胺基醯胺衍生物
CO5680411A2 (es) Compuestos del 1-fenil-2-dimetilamino-metil-ciclohexano, para la terapia de sintomatologia depresiva, dolor e incontinencia
Mahaney et al. Structure− Activity Relationships of the Cycloalkanol Ethylamine Scaffold: Discovery of Selective Norepinephrine Reuptake Inhibitors
JP2003523993A5 (el)
JP7343641B2 (ja) 神経伝達物質放出剤としてのビニローグフェネチルアミン
JP2008532992A (ja) ベンゾキサゾシンおよびそれらの治療的使用
FR2903904A1 (fr) Association de modafinil et d&#39;un antagoniste ou agoniste inverse du recepteur h3
HK1138566A1 (en) Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators